Financing channel feed

Cor­ner Ther­a­peu­tics to hy­per­ac­ti­vate ‘the brains of the im­mune sys­tem’ with $54M launch

Last year
Startups

Bris­tol My­ers pitch­es in to Pathios’ $25M Se­ries B for GPCR in­hibitor

Last year
R&D

ARCH-backed start­up Met­sera launch­es with $290M to take on obe­si­ty gi­ants

Last year

Canaan adds $100M+ to boost bio­phar­ma in­vest­ing, brings on for­mer Pfiz­er ex­ec

Last year
People

In lat­est turn to au­toim­mune ther­a­pies, Cul­li­nan nabs $280M to join lu­pus space

Last year
R&D

Ex­clu­sive: Eat­ing dis­or­der tele­health start­up Equip rais­es $35M, ac­cord­ing to fil­ing

Last year
Health Tech

Re­gen­eron en­ters ven­ture in­vest­ing with $500M, poach­es se­nior part­ner from ARCH

Last year
People

Obe­si­ty drug­mak­er lands first bio­phar­ma up­list­ing on­to Nas­daq since last sum­mer

Last year
Startups

In­vestors aren't back­ing fer­til­i­ty star­tups like they used to — part of dig­i­tal health's re­set

Last year
Health Tech

An­oth­er ADC biotech reels in big bucks as Mark Alles’ TORL nabs $158M

Last year
Startups

Big come­back? The Q1 re­port on biotech is in, and there’s been some sput­ter­ing

Last year
Deals
Bioregnum

Up­dat­ed: Steve Paul, Daphne Zo­har re­unite for an­oth­er neu­ro start­up af­ter Karuna suc­cess

Last year
People
Startups

Two ex-blue­bird lead­ers launch Nvel­op with $100M to tack­le the biggest prob­lem in gene edit­ing

Last year

Health tech star­tups raised $2.7B last quar­ter. It's the low­est Q1 to­tal in five years

Last year
Health Tech

Medicxi backs Chi­nese biotech's next-gen KRAS G12C drug with $40M in­jec­tion

Last year
China

For­eign in­vestors fled Chi­nese biotech af­ter the pan­dem­ic. They still haven’t come back

Last year
China

Con­tineum prices $110M IPO as IPF and neu­ro drugs ad­vance

Last year
Startups

Ex­clu­sive: Ex-Re­cur­sion team launch­es Leash Bio, chal­leng­ing AI field with its bet on need­ing more da­ta

Last year
AI

Ob­sid­i­an Ther­a­peu­tics rakes in $160M for sol­id tu­mor cell ther­a­py pro­gram

Last year
Cell/Gene Tx

Ex­clu­sive: Backed with $350M, se­cre­tive start­up Met­sera jumps in­to the obe­si­ty race

Last year
Startups

Apogee, Spyre founder launch­es its third biotech and heads straight to Nas­daq

Last year
Startups
Deals

Al­terome rais­es $132M to take next-gen can­cer drugs aimed at the 'un­drug­gable' in­to clin­ic

Last year
R&D

An­ti­body biotech Di­ag­o­nal Ther­a­peu­tics lands $128M to pur­sue rare dis­eases

Last year
Startups

Neu­roster­ix emerges with $63M to fol­low Karuna, Cerev­el

Last year
Startups
First page Previous page 16171819202122 Next page Last page
A service from the Financial Times